Raymond James Downgrades Galmed Pharmaceuticals to Market Perform
Raymond James analyst Steven Seedhouse downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Outperform to Market Perform.
80 Biggest Movers From Yesterday
Gainers
Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 211 companies set new 52-week lows.
HC Wainwright & Co. Downgrades Galmed Pharmaceuticals to Neutral
HC Wainwright & Co. analyst Ed Arce downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Neutral.
Galmed Pharmaceuticals Q4 EPS $(0.30), Inline
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. This is a 37.5 percent increase over losses of $(0.48) per share from the same period last year.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
Galmed’s Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD)
Galmed Pharmaceuticals Q3 EPS $(0.31) Beats $(0.36) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.36) by 13.89 percent. This is a 3.13 percent increase over losses of $(0.32) per share
Galmed Announces New Positive Data From Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect On Fibrosis Improvement
-- Updated liver histology data from first 20 patients show 60% fibrosis improvement by at least 1 stage as early as 24 weeks, data will be presented at AASLD Late Breaker Presentations --
-- Statistically